From Static Snapshots to Ongoing Insights: Serial Assessment in Preventive Cardiology
Preventive cardiology has long relied on a single snapshot in time. We assess risk, initiate therapy, and often assume benefit without being able to directly observe how the disease itself responds. While this approach has guided care for decades, it leaves a critical question unanswered: What do we do with this information, and how does it change management?
Advances in cardiac CT and AI-driven quantitative plaque analysis are beginning to shift that paradigm. We now have the ability to not only identify coronary disease, but also quantify its extent and reassess it over time.
Beyond Stenosis: Integrating Plaque Morphology and FFRct for Lesion-Level Risk Assessment
Total plaque volume at the patient or vessel level is an important starting point, but it is not the full story. The next step is moving toward lesion-level assessment. By integrating plaque burden and morphology with physiologic data such as FFRct, we can begin to identify lesions that may pose a higher risk, even when stenosis does not fully reflect the underlying plaque burden.
This reinforces a key point: often, no single metric is sufficient. Plaque characteristics, physiology, and anatomy each provide independent prognostic value. When considered together, they offer a more complete and clinically meaningful assessment of coronary disease.
The Role of Serial Plaque Imaging in Evaluating Treatment Efficacy and Plaque Regression
One of the most compelling opportunities in plaque analysis is the ability to monitor change over time. By establishing a quantitative baseline, clinicians can reassess disease after escalating preventive therapy and determine whether plaque is stabilizing, progressing, or improving.
Although there are no formal guidelines for serial plaque imaging today, selectively reassessing patients in whom therapy has changed can provide valuable insight. In my experience, serial physiologic assessment has demonstrated stabilization and improvement over time, and favorable changes in physiology likely reflect improvements in plaque and morphology as well.
This shifts preventive cardiology from assumption to observation. Instead of relying solely on surrogate markers, we can begin to directly evaluate whether interventions are having the intended effect on coronary disease.
Proactive Preventive Care: Using Serial Plaque Baselines to Inform Treatment Decisions
Quantitative plaque analysis also highlights an important reality: patients do not all respond to therapy in the same way. Some may require more aggressive or combination strategies, while others may benefit from alternative approaches.
Over time, CT-derived plaque characteristics may help identify which patients are more likely to respond to specific therapies. This has the potential to move preventive cardiology away from a uniform treatment model and toward more individualized decision-making grounded in observable disease features.
We are still early in this evolution, and outcome data will take time to mature. But the ability to quantify disease, establish a baseline, and reassess change represents a meaningful step forward. Serial assessment offers a path toward more proactive, informed, and responsive preventive care, where treatment decisions are guided by how coronary disease itself is behaving over time.
See CAD. Manage for life.
